• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Future cardiology

    Future cardiology

    JournalISSN 1479-6678eISSN 1744-8298中科院 医学 4区

    年发文量

    研究主题

    论文(16350)

    排序
    1Recent Advances and Translational Challenges of Potassium Channel Openers in Cardiovascular Medicine: a Narrative Review
    Sasan Shafiei, Zahra Nemati,Alireza Arzhangzadeh, Ali Parouhan, Mohammadesmaeil Aramesh Boroujeni,Rezvan Alizade, Armina Torabian,Salma Nozhat,Amin Zaki Zadeh, Amin Sedokani

    Cardiovascular diseases remain a leading cause of global mortality. Potassium channel openers (PCOs) offer cardioprotective effects through modulation of cellular excitability and mitochondrial function. This narrative review critically evaluates mechanistic and clinical evidence published between 2000 and 2024, focusing on nicorandil and diazoxide in ischemia-reperfusion injury and cardiotoxicity. We examine mitochondrial ATP-sensitive potassium (mitoKATP) and large-conductance calcium-activated potassium (BKCa) channels, their roles in mitochondrial energetics and redox homeostasis, and their interplay with inhibition of mitochondrial permeability transition pore opening. Clinical contexts include cardioplegic arrest, myocardial infarction, and chemotherapy-induced cardiotoxicity. PCOs, particularly nicorandil, combine mitochondrial protection with hemodynamic benefits, with evidence supporting reductions in major adverse cardiovascular events and preservation of mitochondrial integrity. However, routine clinical integration remains constrained by translational gaps, inconsistent electrophysiological effects, and dose-limiting adverse events, including hypotension. Future development should prioritize mitochondrial channel subtype selectivity, particularly targeted mitoKATP and BKCa modulation, alongside well-designed randomized controlled trials to establish clinical efficacy and safety. These advances may strengthen the role of PCOs in cardiovascular medicine while minimizing systemic vascular adverse effects.

    2026
    引用
    AI阅读
    加入学术空间
    2The Prognostic Value of the Triglyceride-Glucose Index in Individuals with Hypertension
    Lanfranco D’Elia,Ferruccio Galletti,Ersilia La Fata, Claudia Ciampa, Vittorio Salvatore, Saverio Stranges

    Hypertension frequently coexists with metabolic abnormalities that contribute to cardiovascular risk. The triglyceride-glucose (TyG) index is a simple surrogate marker of insulin resistance that may also reflect early cardiometabolic and cardiovascular vulnerability. This narrative review examines the prognostic relevance of TyG for all-cause mortality, cardiovascular mortality, and fatal or non-fatal cardiovascular events in hypertension. PubMed, Embase, and the Cochrane Library were searched through 5 October 2026, without date or language restrictions. Evidence from primary hypertensive cohorts generally supports associations between higher TyG and adverse outcomes, although their magnitude and shape vary, with both linear and nonlinear patterns reported. Findings are most consistent among hypertensive patients with diabetes, whereas results from other high-risk settings and hypertension-specific subgroup analyses are more heterogeneous. Differences in TyG calculation, modeling, glycemic status, clinical settings, and overlapping cohorts complicate comparisons across studies. Overall, TyG may represent a readily available, low-cost marker of early cardiometabolic and cardiovascular vulnerability, beyond its role as a surrogate of insulin resistance, with potential to refine cardiovascular risk stratification in hypertension. Further prospective validation should establish its incremental predictive value beyond conventional cardiovascular risk factors and established risk scores.

    2026
    引用
    AI阅读
    加入学术空间
    3Evaluation of a Novel Transseptal Puncture Device for Use in Cardiac Procedures Requiring Left Atrial Access
    Rachael W. Quinn,Gagan D. Singh,Adrian Ebner,Chetan Pasrija,AlleaBelle Bradshaw, Christopher Rumer, David Mester, Cameron Purcell,James S. Gammie

    Transseptal puncture (TSP) is the first step in percutaneous left-heart interventions including atrial fibrillation ablation, left atrial appendage occlusion, and percutaneous mitral valve repair/replacement. Current TSP techniques remain limited by suboptimal imaging visualization, lack of precise control over puncture sites, and a steep learning curve. The Protaryx transseptal puncture device was designed to address these limitations by incorporating a novel atraumatic highly echogenic deployable and retractable nitinol mesh end effector mounted on an extendable catheter. The key advantages of the Protaryx TSP device are the maneuverability of the extendable catheter and the visibility of the end effector that combine to enable precise targeting of the fossa ovalis during TSP. Here, we provide an overview of challenges with transseptal puncture, an overview of the Protaryx device, and early clinical evidence. This includes results of the 5-patient prospective non-randomized observational first-in-human experience with the Protaryx TSP catheter. This study demonstrated early feasibility and safety, with rapid on-target puncture of the fossa ovalis, zero adverse events, and 100% success of structural heart interventions following TSP. The United States Food and Drug Administration (FDA) approval of the Protaryx device has increased options for interventional cardiologists and electrophysiologists seeking to streamline left-sided structural heart intervention.

    2026
    引用
    AI阅读
    加入学术空间
    4Clinical Effectiveness of Outpatient Cardiac Rehabilitation According to Myocardial Injury after Acute Myocardial Infarction
    Takashi Kataoka, Ryoga Kawabata, Kazuki Watarai, Satoshi Terashima, Shinichiro Takeda,Shun Matsunaga, Kunihiko Takahara,Kumiko Mamiya,Kazuhiro Harada,Tomoyuki Nagao,Norihiro Shinoda,Ken Harada,
    2026
    引用
    AI阅读
    加入学术空间
    5Preventing Pacing-Induced Cardiomyopathy Through Early Risk Stratification
    Ergi Duli, Souzan Yacob, Maria Luz Garagiola, Jose Llorente Rodríguez,Sanoj Chacko,Adrian Baranchuk
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 16350 篇论文

    高被引作者

    作者引用发文
    Jennifer Robinson51511
    den Hartigh Laura J21302
    Alan Chait21302
    Nazzareno Galiè14125
    Horst Olschewski12942
    Michael J. Gerber12841
    Vallerie V. McLaughlin12841
    Ellen B. Roecker12841
    Adaani E. Frost12841
    Ronald Oudiz12841

    高产作者

    作者引用发文
    Elena Aikawa50440
    Yunlong Xia38535
    Sebastian Kelle35231
    Bela Merkely38131
    Mingxing Xie27429
    Gregory YH Lip34129
    Shouling Wu23129
    Masanori Aikawa25227
    Yujie Zhou39926
    Yifei Li10725

    相关期刊

    International Journal of Cardiology
    Current Cardiology Reports
    Reviews in cardiovascular medicine
    European Journal Of Heart Failure
    Nature Reviews Cardiology
    Current Problems in Cardiology
    Trends in Cardiovascular Medicine
    Heart Failure Reviews
    Journal of Cardiovascular Development and Disease
    Esc Heart Failure